<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3207218/results/search/disease/results.xml">
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="setting when the availability of a protective vaccine is uncertain." exact="Resistance" post="is often an issue with drugs directed at viral"/>
  <result pre="uncertain. Resistance is often an issue with drugs directed at" exact="viral" post="proteins and for small RNA viruses; there are also"/>
  <result pre="proteins and for small RNA viruses; there are also a" exact="limited" post="number of viral proteins that are amenable to inhibition"/>
  <result pre="small RNA viruses; there are also a limited number of" exact="viral" post="proteins that are amenable to inhibition by a small"/>
  <result pre="may be used as alternative targets. Whereas drugs directed at" exact="viral" post="proteins tend to be virus‐specific, drugs directed at host"/>
  <result pre="on that host function. For influenza virus, we have very" exact="limited" post="knowledge of which cellular factors are involved in virus"/>
  <result pre="export protein RNAi RNA interference siRNA small inhibitory RNA vRNPs" exact="viral" post="ribonucleoprotein complexes INTRODUCTION Influenza viruses belong to the Orthomyxoviridae"/>
  <result pre="have eight genome segments that encode for 10 or 11" exact="viral" post="proteins, depending on the strain. Nine of these proteins"/>
  <result pre="that lies beneath the membrane; the NP that coats the" exact="viral" post="genome; the polymerase complex (PB1, PB1, and PA) that"/>
  <result pre="encapsidated genome; and the nuclear export protein (NEP). The remaining" exact="viral" post="proteins, NS1 and PB1‐F2, are expressed in infected cells"/>
  <result pre="are not packaged into the virus particle. Influenza virus initiates" exact="infection" post="via attachment of HA to sialic acid‐containing proteins on"/>
  <result pre="HA undergoes a conformational change and drives fusion of the" exact="viral" post="envelope with that of the endosome 3. In addition,"/>
  <result pre="interior of the virion and this dissociates M1 from the" exact="viral" post="ribonucleoprotein complexes (vRNPs). The released vRNPs enter the cytoplasm"/>
  <result pre="the nuclear import machinery. Once in the nucleus, the incoming" exact="viral" post="polymerase complex initiates genome transcription. In a process known"/>
  <result pre="responsible for the addition of a poly(A) tail via a" exact="stuttering" post="mechanism 9. PB1 also catalyzes genome replication, which occurs"/>
  <result pre="catalyzes genome replication, which occurs via a positive sense cRNA" exact="intermediate" post="that is an exact copy of the vRNA. In"/>
  <result pre="virus is one of the least well‐understood stages of the" exact="viral" post="life cycle. We know that the viral glycoproteins, HA"/>
  <result pre="stages of the viral life cycle. We know that the" exact="viral" post="glycoproteins, HA and NA, traffic through the endoplasmic reticulum"/>
  <result pre="activation of the cellular innate immune response 17. In the" exact="absence of" post="NS1 expression, influenza virus is rendered non‐pathogenic in an"/>
  <result pre="an immune‐competent host, and thus it is classified as a" exact="viral" post="pathogenicity factor 18. PB1‐F2 is expressed from an alternative"/>
  <result pre="presence in pandemic strains or avian viruses correlates with increased" exact="lung inflammation" post="and pathology, which contributes to increased virulence and therefore"/>
  <result pre="factor encoded by influenza virus 20. In addition to the" exact="viral" post="proteins, there are numerous cellular proteins involved at each"/>
  <result pre="have been identified and characterized through detailed studies of individual" exact="viral" post="proteins, most often interaction studies. However, these likely only"/>
  <result pre="or prevention of influenza and all of these act on" exact="viral" post="proteins (Table 1). Amantadine and rimantadine both target the M2"/>
  <result pre="incoming virus particle and therefore prevent the release of the" exact="viral" post="genome 26. However, because of widespread resistance to these"/>
  <result pre="to these drugs in current circulating viruses, the Centers for" exact="Disease" post="Control (CDC) has recommended that they not be used"/>
  <result pre="drugs for the treatment of influenza Antiviral drug Active against" exact="Viral" post="target Route Recommended use in 2010/2011 Amantadine Influenza A"/>
  <result pre="only. One of the major issues with drugs that target" exact="viral" post="proteins is that resistance is very likely to develop."/>
  <result pre="viruses are 100% resistant. Oseltamivir resistance arose over a relatively" exact="short" post="timescale (three seasons), which was unexpected as it was"/>
  <result pre="have a propensity for developing oseltamivir resistance and this is" exact="acquired" post="by the pandemic H1N1 virus in addition to its"/>
  <result pre="of viruses by virtue of the fact that they target" exact="viral" post="proteins. Understandably, this strategy is used because of the"/>
  <result pre="the target is virus‐encoded and also that there are a" exact="limited" post="number of viral proteins that possess properties amenable to"/>
  <result pre="virus‐encoded and also that there are a limited number of" exact="viral" post="proteins that possess properties amenable to developing pharmaceutically acceptable"/>
  <result pre="functions they rely on is likely to far outnumber the" exact="viral" post="functions, so by identifying these required host factors, we"/>
  <result pre="Maraviroc targets one of the HIV‐1 co‐receptors, C‐C chemokine receptor" exact="type 5" post="(CCR5) 36, and thereby prevents virus entry. Support for"/>
  <result pre="loss of function and who are more resistant to HIV‐1" exact="infection" post="37. Admittedly, maraviroc has also taught us that antiviral"/>
  <result pre="of viruses that use the alternative receptor, C‐X‐C chemokine receptor" exact="type 4," post="which are therefore insensitive to a CCR5‐inhibitor 38. This"/>
  <result pre="it as a drug target. One should also distinguish between" exact="chronic" post="and acute infections, as the length of drug treatment"/>
  <result pre="a drug target. One should also distinguish between chronic and" exact="acute" post="infections, as the length of drug treatment for acute"/>
  <result pre="and acute infections, as the length of drug treatment for" exact="acute" post="infections such as influenza will usually be limited to"/>
  <result pre="acute infections, as the length of drug treatment for acute" exact="infections" post="such as influenza will usually be limited to about"/>
  <result pre="treatment for acute infections such as influenza will usually be" exact="limited" post="to about a week. Therefore, inhibition of a cellular"/>
  <result pre="host‐directed antiviral therapies in this setting, rather than with a" exact="chronic" post="infection. It is also possible that a particular host"/>
  <result pre="in this species. Drosophila cells are not permissive for influenza" exact="virus infection," post="so the authors generated a modified influenza virus. To"/>
  <result pre="the HA gene with that of the glycoprotein from vesicular" exact="stomatitis" post="virus. In the absence of HA, NA is not"/>
  <result pre="that of the glycoprotein from vesicular stomatitis virus. In the" exact="absence of" post="HA, NA is not essential, so they also replaced"/>
  <result pre="infected with the recombinant influenza virus. The authors describe 176" exact="primary" post="hits, of which 110 could be confirmed with alternate"/>
  <result pre="COX6A1, and NXF1) were confirmed to be required for influenza" exact="infection" post="of human cells, indicating that data from Drosophila screens"/>
  <result pre="Yet, all used distinct approaches. Brass et al. 21 infected" exact="osteosarcoma" post="(U2OS) cells with influenza A/PR/8/34 virus for 12 h and"/>
  <result pre="(U2OS) cells with influenza A/PR/8/34 virus for 12 h and monitored" exact="infection" post="by staining for cell surface expression of HA. This"/>
  <result pre="PUSL1, TPST1, and WDR33) were identified as restriction factors because" exact="infection" post="was enhanced in their absence. The first of these"/>
  <result pre="coronavirus 21, 39, 40. König et al. 24 used lung" exact="epithelial" post="carcinoma (A549) cells for their genome‐wide RNAi screen. Using"/>
  <result pre="21, 39, 40. König et al. 24 used lung epithelial" exact="carcinoma" post="(A549) cells for their genome‐wide RNAi screen. Using a"/>
  <result pre="infection. Thus, their screen captured everything from attachment up until" exact="viral" post="gene expression, which was monitored via luciferase activity. They"/>
  <result pre="genes with an siRNA library from Qiagen and reported 295" exact="primary" post="hits for which at least two siRNAs per gene"/>
  <result pre="to be required in the context of wild‐type influenza A/WSN/33" exact="virus infection." post="Karlas et al. 23 also used A549 cells and"/>
  <result pre="siRNA library (22,843 genes targeted) but they used a two‐step" exact="infection" post="process that allowed them to capture the entire influenza"/>
  <result pre="to mid stages of the life‐cycle. The supernatants from this" exact="infection" post="were then transferred onto 293T cells, which contained an"/>
  <result pre="contained an influenza‐specific luciferase reporter that is activated upon influenza" exact="virus infection." post="siRNAs that resulted in reduced luciferase expression here but"/>
  <result pre="a unique aspect of this study. The authors report 287" exact="primary" post="hits from this screening approach, with 168 of these"/>
  <result pre="whereas only two of the 12 were required by vesicular" exact="stomatitis" post="virus. This suggests that these RNAi screens are able"/>
  <result pre="were shown to be transcriptionally regulated in response to influenza" exact="virus infection." post="Finally, 504 genes that encode proteins involved in several"/>
  <result pre="with siRNA pools from Dharmacon. The siRNAs were transfected into" exact="primary" post="human bronchial epithelial cells, and growth of influenza A/PR/8/34"/>
  <result pre="from Dharmacon. The siRNAs were transfected into primary human bronchial" exact="epithelial" post="cells, and growth of influenza A/PR/8/34 virus in these"/>
  <result pre="of the cells to induce interferon‐β in response to (i)" exact="infection" post="with PR8 virus lacking NS1 expression and (ii) transfection"/>
  <result pre="with PR8 virus lacking NS1 expression and (ii) transfection with" exact="viral" post="RNA. A total of 616 genes scored as hits"/>
  <result pre="lacking NS1 expression and (ii) transfection with viral RNA. A" exact="total" post="of 616 genes scored as hits in one of"/>
  <result pre="detail, a list of hits was generated composed of the" exact="primary" post="hits from all five screens. For the Drosophila screen,"/>
  <result pre="point towards interfaces with the virus, for example, interactions with" exact="viral" post="proteins. As an example, NXF1 is described to be"/>
  <result pre="RPS4X, RPS5, RPS10, RPS14, RPS16, RPS20, RPL13A, FAU 2 COPI" exact="vesicle" post="3.72 ARCN1, COPA, COPB1, COPB2, COPG 3 Proton‐transporting V‐type"/>
  <result pre="in that pathway will affect the virus. Therefore, despite the" exact="lower" post="confidence level, useful information can still be obtained by"/>
  <result pre="mRNA processing 9.66 44 7 ABC transporter 9.26 5 8" exact="Protein" post="transport 8.6 4 9 Nucleus 8.04 7 10 Regulation"/>
  <result pre="16 15 Protein‐tyrosine phosphatase, dual specificity 4.31 5 16 COPI" exact="vesicle" post="3.87 14 17 Mitochondrial membrane 3.61 10 18 Ubl"/>
  <result pre="dual specificity 4.31 5 16 COPI vesicle 3.87 14 17" exact="Mitochondrial" post="membrane 3.61 10 18 Ubl conjugation pathway 3.35 16"/>
  <result pre="in the screens, where p27‐deficient mice were shown to have" exact="lower" post="viral titers in their lungs compared with wild‐type mice"/>
  <result pre="the screens, where p27‐deficient mice were shown to have lower" exact="viral" post="titers in their lungs compared with wild‐type mice 23."/>
  <result pre="a drug target. With drug‐mediated inhibition, especially if treating an" exact="acute" post="disease such as influenza, the loss of cellular function"/>
  <result pre="drug target. With drug‐mediated inhibition, especially if treating an acute" exact="disease" post="such as influenza, the loss of cellular function is"/>
  <result pre="translation initiation factor 4A, isoform 2 FAU 2197 Finkel–Biskis–Reilly murine" exact="sarcoma" post="virus (FBR‐MuSV) ubiquitously expressed FBXW2 26190 F‐box and WD"/>
  <result pre="2 FKBP8 23770 FK506 binding protein 8, 38 kDa HAND2 9464" exact="Heart" post="and neural crest derivatives expressed 2 IFNGR2 3460 Interferon"/>
  <result pre="3837 Karyopherin (importin) beta 1 KRAS 3845 v‐Ki‐ras2 Kirsten rat" exact="sarcoma" post="viral oncogene homolog LRP1B 53353 Low density lipoprotein‐related protein"/>
  <result pre="Karyopherin (importin) beta 1 KRAS 3845 v‐Ki‐ras2 Kirsten rat sarcoma" exact="viral" post="oncogene homolog LRP1B 53353 Low density lipoprotein‐related protein 1B"/>
  <result pre="Mdm2 p53 binding protein homolog (mouse) MYC 4609 v‐myc myelocytomatosis" exact="viral" post="oncogene homolog (avian) NTSR1 4923 Neurotensin receptor 1 (high"/>
  <result pre="Phosphogluconate dehydrogenase PLK3 1263 Polo‐like kinase 3 (Drosophila) PPP1R14D 54866" exact="Protein" post="phosphatase 1, regulatory (inhibitor) subunit 14D PRPF8 10594 PRP8"/>
  <result pre="PSENEN 55851 Presenilin enhancer 2 homolog (C. elegans) PTPRN 5798" exact="Protein" post="tyrosine phosphatase, receptor type, N PTS 5805 6‐pyruvoyltetrahydropterin synthase"/>
  <result pre="that may indicate whether these pathways are regulated during influenza" exact="virus infection." post="It is expected that those host factors for which"/>
  <result pre="The fact that multiple such studies were published over a" exact="short" post="time span has provided us the opportunity to assess"/>
  <result pre="ZhangFet alAssembly of endocytic machinery around individual influenza viruses during" exact="viral" post="entry. Nature Structural and Molecular Biology2004; 11: 567–573. 3SkehelJJ,"/>
  <result pre="17: 5844–5852.9755184 7FechterP, BrownleeGG. Recognition of mRNA cap structures by" exact="viral" post="and cellular proteins. Journal of General Virology2005; 86: 1239–1249.15831934"/>
  <result pre="mRNA cap structures by viral and cellular proteins. Journal of" exact="General" post="Virology2005; 86: 1239–1249.15831934 8DiasA, BouvierD, CrepinTet alThe cap‐snatching endonuclease"/>
  <result pre="used by influenza virus RNA polymerase on its cRNA and" exact="viral" post="RNA promoters during viral RNA replication. Journal of Virology2006;"/>
  <result pre="RNA polymerase on its cRNA and viral RNA promoters during" exact="viral" post="RNA replication. Journal of Virology2006; 80: 2337–2348.16474140 11PerezJT, VarbleA,"/>
  <result pre="influenza virus NEP (NS2 protein) mediates the nuclear export of" exact="viral" post="ribonucleoproteins. EMBO Journal1998; 17: 288–296.9427762 13NeumannG, HughesMT, KawaokaY. Influenza"/>
  <result pre="alThe multifunctional NS1 protein of influenza A viruses. Journal of" exact="General" post="Virology2008; 89: 2359–2376.18796704 18Garcia‐SastreA, EgorovA, MatassovDet alInfluenza A virus"/>
  <result pre="under an emergency IND program in the United States. Clinical" exact="Infectious" post="Diseases2011; 52: 695–706.21367722 29IvesJA, CarrJA, MendelDBet alThe H274Y mutation"/>
  <result pre="in vivo. Antiviral Research2002; 55: 307–317.12103431 30BloomJD, GongLI, BaltimoreD. Permissive" exact="secondary" post="mutations enable the evolution of influenza oseltamivir resistance. Science2010;"/>
  <result pre="pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clinical" exact="Infectious" post="Diseases2010; 50: 1252–1255.20345239 32GraitcerSB, GubarevaL, KamimotoLet alCharacteristics of patients"/>
  <result pre="of patients with oseltamivir‐resistant pandemic (H1N1) 2009, United States. Emerging" exact="Infectious" post="Diseases2011; 17: 255–257.21291599 33SeibertCW, KaminskiM, PhilippJet alOseltamivir‐resistant variants of"/>
  <result pre="A(H1N1) viruses maintain fitness and transmissibility in ferrets. Journal of" exact="Infectious" post="Diseases2011; 203: 348–357.21208927 35MalakhovMP, AschenbrennerLM, SmeeDFet alSialidase fusion protein"/>
  <result pre="alSialidase fusion protein as a novel broad‐spectrum inhibitor of influenza" exact="virus infection." post="Antimicrobial Agents and Chemotherapy2006; 50: 1470–1479.16569867 36MacArthurRD, NovakRM. Reviews"/>
  <result pre="the first of a new class of antiretroviral agents. Clinical" exact="Infectious" post="Diseases2008; 47: 236–241.18532888 37DeanM, CarringtonM, WinklerCet alGenetic restriction of"/>
  <result pre="Diseases2008; 47: 236–241.18532888 37DeanM, CarringtonM, WinklerCet alGenetic restriction of HIV‐1" exact="infection" post="and progression to AIDS by a deletion allele of"/>
  <result pre="Hemophilia growth and development study, multicenter AIDS cohort study, multicenter" exact="hemophilia" post="cohort study, San Francisco City cohort, ALIVE study. Science1996;"/>
  <result pre="of the vacuolar H(+)‐ATPase in animal virus entry. Journal of" exact="General" post="Virology1994; 75(Pt 10): 2595–2606.7931146 43GuineaR, CarrascoL. Requirement for vacuolar"/>
  <result pre="dependence on cellular NXF1/TAP for their nuclear export. Journal of" exact="General" post="Virology2010; 91: 1290–1301.20071484 45SatterlyN, TsaiPL, van DeursenJet alInfluenza virus"/>
 </snippets>
</snippetsTree>
